Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Shares Outstanding (Weighted Average) (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Shares Outstanding (Weighted Average) for 12 consecutive years, with $27.6 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) fell 57.27% year-over-year to $27.6 million; the TTM value through Mar 2026 reached $27.6 million, down 57.27%, while the annual FY2025 figure was $27.6 million, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) hit $27.6 million in Q1 2026 for Crescent Biopharma, roughly flat from $27.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $64.5 million in Q1 2025 and bottomed at $13.9 million in Q2 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $50.0 million, with a median of $56.4 million recorded in 2022.
  • Year-over-year, Shares Outstanding (Weighted Average) rose 20.58% in 2023 and then crashed 78.46% in 2025.
  • Crescent Biopharma's Shares Outstanding (Weighted Average) stood at $52.5 million in 2022, then rose by 20.58% to $63.3 million in 2023, then grew by 1.8% to $64.5 million in 2024, then tumbled by 57.27% to $27.6 million in 2025, then increased by 0.06% to $27.6 million in 2026.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $27.6 million, $27.6 million, and $13.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.